Cdymax

Cdymax is a clinical-stage biotechnology company based in Beijing, China, focused on the discovery and development of next-generation therapies using targeted protein degradation (TPD) and protein stabilization technologies. Founded in 2020 by Dr. Xiaoqiang Yan, the company leverages a proprietary platform to design innovative small molecules, including PROTACs and molecular glues, that modulate the body's natural ubiquitin-proteasome system. Their research primarily targets oncogenic and immunological proteins that have traditionally been considered "undruggable" by conventional inhibitors. Cdymax is advancing a diverse pipeline of candidates through preclinical and early clinical development, supported by significant investment from leading venture capital firms. The company aims to provide transformative treatments for patients with difficult-to-treat cancers and autoimmune diseases.